HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.
HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.